

Successful Craniotomy for Advanced Basal Cell Carcinomas with Cranial Bone Invasion and Dura Mater Infiltration - Unique Presentation in a Bulgarian Patient

Slavomir Kondoff¹, Atanas Drenchev², Torello Lotti³, Uwe Wollina⁴, Ilija Lozev⁵, Ivan Pidakev⁵, Ivan Terziev⁶, Yavor Grigorov⁷, Serena Gianfaldoni³, Georgi Tchernev^{8,9*}

¹Okrajna Bolnica - Neurosurgery Sofia, Sofia, Bulgaria; ²University Hospital Saint Anna - Neurosurgery Sofia, Sofia, Bulgaria; ³University G. Marconi of Rome, Institute of Dermatology, Rome, Italy; ⁴Städtisches Klinikum Dresden, Department of Dermatology and Allergology, Friedrichstrasse 41, Dresden, Germany; ⁵Medical Institute of Ministry of Interior, Department of General, Vascular and Abdominal Surgery, General Skobelev 79, 1606 Sofia, Bulgaria; ⁶University Hospital Tsaritsa Ioana, Department of Common and Clinical Pathology, Sofia, Bulgaria; ⁷Department of Orthopedics and Traumatology, University Hospital Lozenetz, Koziak 1 Street, Sofia, Bulgaria; ⁸Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, General Skobelev Nr 79, Sofia, Bulgaria; ⁹Onkoderma - Polyclinic for Dermatology and Dermatologic Surgery, General Skobelev 26, Sofia, Bulgaria

Abstract

Citation: Kondoff S, Drenchev A, Lotti T, Wollina U, Lozev I, Pidakev I, Terziev I, Grigorov Y, Gianfaldoni S, Tchernev G. Successful Craniotomy for Advanced Basal Cell Carcinomas with Cranial Bone Invasion and Dura Mater Infiltration - Unique Presentation in a Bulgarian Patient. Open Access Maced J Med Sci. 2018 Feb 15; 6(2):372-375. <https://doi.org/10.3889/oamjms.2018.101>

Keywords: Surgery; Craniotomy; Basal cell carcinomas; Treatment outcome; Treatment approach

***Correspondence:** Georgi Tchernev. Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, General Skobelev Nr 79, Sofia, Bulgaria. E-mail: georgi_tchernev@yahoo.de

Received: 02-Dec-2017; **Revised:** 26-Jan-2018; **Accepted:** 28-Jan-2018; **Online first:** 14-Feb-2018

Copyright: © 2018 Slavomir Kondoff, Atanas Drenchev, Torello Lotti, Uwe Wollina, Ilija Lozev, Ivan Pidakev, Ivan Terziev, Yavor Grigorov, Serena Gianfaldoni, Georgi Tchernev. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

Funding: This research did not receive any financial support

Competing Interests: The authors have declared that no competing interests exist

BACKGROUND: Basal cell carcinomas (BCC) located in the sun-exposed regions are a serious therapeutic challenge. Therefore early diagnosis and adequate therapy should be of a high priority for every dermatologic surgeon.

CASE PRESENTATION: We are presenting a patient with multiple BCCs, located on the area of the scalp, who had been treated several years ago with electrocautery and curettage after histopathological verification. However, the last few years the tumours have advanced, infiltrating firstly the tabula externa and a year later the tabula interna of the cranium. A computed tomography (CT) imaging and radiography of the skull were performed to reveal the definite tumour localisation, needed for planning an one - step surgical intervention. Both of the instrumental examinations confirmed the existence of osteolytic tumour lesions. Craniotomy with precise removal of the BCCs infiltrating the cranial bone in all of its thickness was performed. Partial resection of dura mater was also performed also because intraoperative findings established the involvement of the dura. Histopathological verification revealed bone and dural invasion with clean resection margins. The bone defect was recovered with hydroxyapatite cement. Reconstruction as the shape of the skull was carefully modified and adapted to its initial size and form. Layered closure of the skin and soft tissues were performed after the complete removal of the BCCs. The postoperative period had no serious complications.

CONCLUSION: Precisely managed therapy of BCC is curative in most of the cases as it ensures good prognosis for the patient.

Introduction

Basal cell carcinoma (BCC) is non - melanocytic skin epithelial tumour arising from the basal layer cells of the epidermis [1]. In the last few years, world statistics show rapidly increasing incidence rate as the lifetime risk is reaching nearly 30% [2]. Although BCC does not demonstrate significant metastatic tendency, its local destructive and infiltrative nature, as well as its tendency to

receive turns, is into a serious medical problem, which should not be neglected [3]. Since exposure to UV - radiation is the main etiological factor of BCC, prevalent locations of the lesions are the face and the head, and scalp is the most commonly affected area [4]. Behind the acronym "SCALP" stands its five structural layers - skin, subcutaneous tissue, aponeurosis, loose areolar tissue, and periosteum. In cases of highly progressive local invasion, the tumour process infiltrates galea aponeurotica, periosteum, calvaria, superficial and deep layers of dura mater and the underlying brain [5] successively. At this stage, the

invasion of deeper tissues compromises treatment opportunities for achieving an optimal therapeutic result; it reflects on the long-time survival of the patient and increases healthcare costs as well [6].

Therefore, precise diagnostic approach and accurate therapeutic strategies are mandatory for prevention of any further complications which at a later stage could be fatal.

Case report

We present a 68 – year - old patient with multiple primary infiltrative BCCs in the scalp area initially treated 14 years ago with superficial contact X-ray therapy, end does 60 greys, followed by electrocautery (x2) several years later (Figure 1a). He presented to the dermatologic policlinic for diagnosis and therapy of two newly - formed pigmented lesions located in the left parietal region. Also, two chronic non - healing ulcerative wounds were observed in the same area which had occurred 6 years ago according to anamnestic data. An uncomfortable, itchy, burning sensation in the region was reported as a subjective complaint (Figure 1a - d). Somatic and neurological status as well as paraclinical assessment and chest X-ray examinations did not show any abnormalities. Profile radiography of the skull detected two osteolytic zones with irregular borders in the parietal region; no structural changes were observed.




Figure 1: a) Clinical suspicion of 2 pigmented basal cell carcinomas, located next to the area of 2 ulcerated lesions. The ulcerated lesions are histologically confirmed as basal cell carcinomas; b) One year later wide expansion of the ulcerative lesions is observed with the addition of pain and bleeding; c) 4 months later 2 hyperkeratotic tumor formations with blood/yellow discharge have appeared; d - f) CT - examination of the lesions revealed progression in depth and involvement of tabula interna of the tumor process (one year earlier CT - examination detected tumor infiltration only in tabula externa)

Cranial computed - tomography (CT) examination performed in June 2017 revealed two deformities in the form of tumour-mediated osteolysis, affecting the diploe of the tabula externa on the left parietal and parasagittal areas. Several months later, in November 2017 second cranial CT examination

detected progression of the infiltrative process as two zones of osteolytic changes, affecting the tabula externa and the diploe of tabula interna (Figure 1d - 1f).

Complete excision with removal of periosteum and partial removal of the tabula externa was performed in collaboration with the neurosurgical team (Figure 2a, 2b). Intraoperative findings showed tumour infiltration of the parietal bone and the superficial layer of dura mater. This neoplastic formation was surgically removed in maximal safety margins. Thermal ablation of dura mater was performed as the tabula interna remained intact (Figure 2c - 2e). Hydroxyapatite cement was used for reconstruction of the cranial bone defect (Figure 2f - 2g). After meticulous haemostasis and layered soft tissue suturing, the surgical wound was covered with a sterile Bactrigrass dressing. The patient was referred to the plastic surgery department for reconstruction of the skin defect.




Figure 2: a) Careful dissection of the skin around the tumor with a wide margin of surgical safety; b) Skin defect as a result from complete dissection of the skin around the area of the tumors; c) In the 4 corners of a provisional rectangle surrounding the tumors 4 defects are situated via high-frequency drill with a set of specific heads. Dura mater remains intact. Severe bleeding was stopped with an electric knife; d) Clinical finding after locating of additional bone defects in the calvarium region; e) Careful removal of the cranial parts infiltrated by a tumour as well as part of dura mater with neoplastic involvement. Haemostasis; f) Applying hydroxyapatite bone cement for reconstruction of the cranial defect; g) Precise adaptation of the cement before hardening; h) Layered soft tissue closure after the surgical removal of the lesions; i) Postoperative status after adaptation

Histological examination revealed basal cell carcinoma invasion with clear surgical margins.




Figure 3: 3a – Histopathological data of basal cell carcinoma infiltrating the bone. Unsuccessful pathologic sample; 3b – Routine postoperative CT-imaging of the patient is showing relatively good adaptation of the cement to the normal cranial structure; 3c – Early postoperative CT of the patient. Inapparent finding. CT 3 days after surgical approach with cranial bone resection because of postoperatively reduced sensitivity of the right part of the body, suspected for ischemic insult

Discussion

We present to the dermatological and oncosurgical community a clinical case of a patient with basal cell carcinoma who developed recurrent neoplastic lesions with the progressive invasion of the skull due to incorrect treatment. The main principle for treatment of any malignant lesions including BCC is radical surgical elimination insufficient field of surgical safety [7].

As it is stated in the National Comprehensive Cancer Network (NCCN), the aim of treatment for BCC is the elimination of a tumour with maximal preservation of function and physical appearance [8]. The therapeutic strategy should be individualised to every patient according to the size, location and depth of a tumour as well as comorbidity and additional examination findings [9]. However, in any case, there is a simple rule of great importance that should always be followed when it refers to surgical management, and it is the definitive requirement of radical surgical approach. Any ignorance of this principle is a potential triggering factor for neoplastic development [10]. For this particular reason in most cases radical surgical excision with histopathological evaluation and regular dermatological follow up is the first line treatment for BCC [11]. In cases of more difficult to treat lesions, Mohs micrographic surgery is considered an eligible and reasonable option [12].

There are various alternative non - surgical methods for the treatment of BCC [13]. Radiation therapy is a standard therapeutic option for patients with contraindications for surgery, but it can also be used as adjuvant therapy [14]. However, according to the Guideline recommendations on BCC, it is not recommendable as first-line treatment if surgical excision is possible [15]. Curettage and cautery, as well as cryosurgery and laser ablative therapy, show variable recurrence rates and may be considered as a good treatment only for low-risk BCC [16]. Local therapy with chemotherapeutic and immune - modulating agents such as topical Imiquimod 5% or Fluorouracil may be indicated in some cases of small and superficial BCC [17]. Topical photodynamic therapy is another option, appropriate for superficial and thin nodular BCC in patients with large or multiple lesions and those in sites of high cosmetic importance [18].

A Hedgehog (Hh) pathway inhibitor (Vismodegib, Sonidegib) can be used for locally advanced BCC in patients with contraindications for surgical or radiation therapy as well as for post-treatment recidives and metastatic forms of BCC [19].

Unfortunately, according to the anamnestic data of our patient it can be concluded either that he had been treated several times with an inadequate treatment modality or that the electrocauterisation was not performed in enough margins.

Although BCC in the area of the head is commonly seen, the risk of involvement of the skull and dura mater is extremely rare with an estimated incidence of 0.03% [20]. According to a PubMed search, there are only 13 cases of BCC of the scalp with intracranial tumour invasion described in the world literature till now. Local excision of the scalp in combination with craniectomy with dural resection (if needed) is the standard surgical treatment in such cases [21]. It is followed by reconstruction of the bone defects (cranioplasty) using fascial graft for dura mater, and bone cement (calcium hydroxyapatite) and titanium mesh for the skull [22]. Skin and soft tissue defects are reconstructed using island flaps, rotational flaps or free tissue transfer [23][24]. Depending on the depth of tumour invasion, curettage of the tabula externa is a less traumatic therapeutic option which does not need any further osteoplasty. It is indicated in limited cases where the tumour process has superficial spreading and evolves only part of the cranium's thickness [25]. Both surgical techniques require clear surgical bone margins [26]. Surgical management of BCC is a serious challenge for the operating team in cases of neglected patients or histopathological subtypes of BCC with aggressive behaviour, represented as rapid growth into large sizes [27].

It is important to keep in mind that an infiltrative tumour process can be inapparent for a long time which reaffirms that every lesion should not be evaluated but removed concerning all principles of the good oncosurgical practice [28]. Precisely managed therapy of BCC is curative in most of the cases as it ensures good prognosis for the patient [29]. However, it shows high recurrence rate with risk of extensive invasion if there is not complete surgical removal [30].

References

1. Lima NL, Verli FD, de Miranda JL, Marinho SA. Basosquamous Carcinoma: Histopathological Features. *Indian Journal of Dermatology*. 2012; 57(5):382-383. <https://doi.org/10.4103/0019-5154.100489> PMID:23112359 PMCID:PMC3482802
2. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. *BMJ : British Medical Journal*. 2003; 327(7418):794-798. <https://doi.org/10.1136/bmj.327.7418.794> PMID:14525881 PMCID:PMC214105
3. Marzuka AG, Book SE. Basal Cell Carcinoma: Pathogenesis, Epidemiology, Clinical Features, Diagnosis, Histopathology, and Management. *The Yale Journal of Biology and Medicine*. 2015; 88(2):167-179. PMID:26029015 PMCID:PMC4445438
4. Situm M, Buljan M, Bulat V, Lugović Mihaljčić L, Bolanca Z, Simić D. The role of UV radiation in the development of basal cell carcinoma. *Coll Antropol*. 2008; 32(Suppl 2):167-70. PMID:19138022
5. Donald PJ, Boggan J, Farwell DG, Enepekides DJ. Skull Base Surgery for the Management of Deeply Invasive Scalp Cancer. *Skull Base*. 2011; 21(6):343-350. <https://doi.org/10.1055/s-0031->

- [1284216](#) PMID:22547959 PMCID:PMC3312126
6. Morselli P, Tosti A, Guerra L, Fanti PA, Fedeli F, Pistorale T, Cavina C, Varotti C. Recurrent basal cell carcinoma of the back infiltrating the spine. Recurrent basal cell carcinoma. *J Dermatol Surg Oncol*. 1993; 19(10):917-22. <https://doi.org/10.1111/j.1524-4725.1993.tb00979.x> PMID:8408910
7. Berking C, Hauschild A, Kölbl O, Mast G, Gutzmer R. Basal Cell Carcinoma—Treatments for the Commonest Skin Cancer. *Deutsches Ärzteblatt International*. 2014; 111(22):389-395. PMID:24980564 PMCID:PMC4078227
8. Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Higgins SA, Ho AL, Lewis KD, Lydiatt DD, Nehal KS, Nghiem P, Olsen EA, Schmultz CD, Sekulic A, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Wong SL, Zic JA, Hoffmann KG, Engh A. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2016; 14(5):574-97. <https://doi.org/10.6004/jnccn.2016.0065> PMID:27160235
9. Di Stefani A, Del Regno L, Piccerillo A, Peris K. Practical indications for the management of non-melanoma skin cancer patients. *G Ital Dermatol Venereol*. 2017; 152(3):286-294. PMID:28195452
10. Patel SS, Cliff Sh, Ward Booth P. Incomplete removal of basal cell carcinoma: what is the value of further surgery? *Oral and Maxillofacial Surgery*. 2013; 17(2):115-118. <https://doi.org/10.1007/s10006-012-0348-3> PMID:22868984 PMCID:PMC3661037
11. Clark CM, Furniss M, Mackay-Wiggan JM. Basal cell carcinoma: an evidence-based treatment update. *Am J Clin Dermatol*. 2014; 15(3):197-216. <https://doi.org/10.1007/s40257-014-0070-z> PMID:24733429
12. Berking C, Hauschild A, Kölbl O, Mast G, Gutzmer R. Basal Cell Carcinoma—Treatments for the Commonest Skin Cancer. *Deutsches Ärzteblatt International*. 2014; 111(22):389-395. PMID:24980564 PMCID:PMC4078227
13. Lanoue J, Goldenberg G. Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies. *The Journal of Clinical and Aesthetic Dermatology*. 2016; 9(5):26-36. PMID:27386043 PMCID:PMC4928477
14. Khan L, Breen D, Zhang L, et al. Predictors of recurrence after radiotherapy for non-melanoma skin cancer. *Current Oncology*. 2014; 21(2):e326-e329. <https://doi.org/10.3747/co.21.1727> PMID:24764714 PMCID:PMC3997462
15. Lee WR, Mendenhall WM, Parsons JT, Million RR. Radical radiotherapy for T4 carcinoma of the skin of the head and neck: a multivariate analysis. *Head Neck*. 1993; 15(4):320-4. <https://doi.org/10.1002/hed.2880150409> PMID:8360054
16. Trakatelli M, Morton C, Nagore E, Ulrich C, Del Marmol V, Peris K, Basset-Seguín N. Update of the European guidelines for basal cell carcinoma management. *European Journal of Dermatology*. 2014; 24(3):312-29. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. *Arch Dermatol*. 2009; 145(12):1431-8.
18. Ericson MB, Wennberg A-M, Larkö O. Review of photodynamic therapy in actinic keratosis and basal cell carcinoma. *Therapeutics and Clinical Risk Management*. 2008; 4(1):1-9.
19. Silapunt S, Chen L, Migden MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. *Therapeutic Advances in Medical Oncology*. 2016; 8(5):375-382. <https://doi.org/10.1177/1758834016653605> PMID:27583029 PMCID:PMC4981290
20. Kleydman Y, Manolidis S, Ratner D. Basal cell carcinoma with intracranial invasion. *J Am Acad Dermatol*. 2009; 60(6):1045-9. <https://doi.org/10.1016/j.jaad.2008.10.005> PMID:19467376
21. Kwon CS, Al Awar O, Ripa V, Said G, Rocka S. Basal cell carcinoma of the scalp with destruction and invasion into the calvarium and dura mater: Report of 7 cases and review of literature. *Journal of Clinical Neuroscience*. 2018; 47:190-7. <https://doi.org/10.1016/j.jocn.2017.09.028> PMID:29074315
22. Wei FC, Tsao SB, Chang CN, Noordhoff MS. Scalp, skull, and dura reconstruction on an emergency basis. *Ann Plast Surg*. 1987; 18(3):252-6. <https://doi.org/10.1097/0000637-198703000-00014> PMID:3592514
23. Lutz BS, Wei FC, Chen HC, Lin CH, Wei CY. Reconstruction of scalp defects with free flaps in 30 cases. *Br J Plast Surg*. 1998; 51(3):186-90. <https://doi.org/10.1054/bjps.1997.0182> PMID:9664876
24. Wang HT, Erdmann D, Olbrich KC, Friedman AH, Levin LS, Zenn MR. Free flap reconstruction of the scalp and calvaria of major neurosurgical resections in cancer patients: lessons learned closing large, difficult wounds of the dura and skull. *Plast Reconstr Surg*. 2007; 119(3):865-72. <https://doi.org/10.1097/01.prs.0000240830.19716.c2> PMID:17312489
25. Çöloğlu H, Özkan B, Şener M, Uysal AÇ, Borman H. The management of non-melanocytic skin malignancies of the scalp and calvarium. *Indian Journal of Plastic Surgery: Official Publication of the Association of Plastic Surgeons of India*. 2014; 47(1):36-42. <https://doi.org/10.4103/0970-0358.129621> PMID:24987202 PMCID:PMC4075214
26. Nahhas AF, Scarbrough CA, Trotter S. A Review of the Global Guidelines on Surgical Margins for Nonmelanoma Skin Cancers. *The Journal of Clinical and Aesthetic Dermatology*. 2017; 10(4):37-46. PMID:28458773 PMCID:PMC5404779
27. Deshmukh P, Sharma YK, Dogra BB, Chaudhari ND. Superficial Large Basal Cell Carcinoma Over Face, Reconstructed by V-Y Plasty. *Journal of Cutaneous and Aesthetic Surgery*. 2014; 7(1):65-66. <https://doi.org/10.4103/0974-2077.129992> PMID:24761108 PMCID:PMC3996799
28. Ruini C, Hartmann D, Saral S, Krammer S, Ruzicka T, von Braunmühl T. The invisible basal cell carcinoma: how reflectance confocal microscopy improves the diagnostic accuracy of clinically unclear facial macules and papules. *Lasers Med Sci*. 2016; 31(8):1727-1732. <https://doi.org/10.1007/s10103-016-2043-3> PMID:27492373
29. Puig S, Berrocal A. Management of high-risk and advanced basal cell carcinoma. *Clin Transl Oncol*. 2015; 17(7):497-503. <https://doi.org/10.1007/s12094-014-1272-9> PMID:25643667 PMCID:PMC4495248
30. Mahvash M. Intracranial basal cell carcinoma with extensive invasion of the skull base. *Turk Neurosurg*. 2014; 24(4):571-3. <https://doi.org/10.5137/1019-5149.JTN.8612-13.0>